Talking to PatientsBack

Talking to PatientsBack

Count on ArestinProfessional.com
to Help You Educate Patients

Talk to patients about the risks associated with periodontal disease and set expectations prior to treating with ARESTIN® + SRP.

Treatment education tools can be used to reinforce the importance of your recommended treatment plan and to educate and engage patients to play an active role in their treatment of periodontal disease.

Patients Want to Be Educated by You, Their Dental Healthcare Professional

Download the ARESTIN® Patient Brochure to help explain gum disease and your recommended treatment plan.

dental patient education periodontitis socransky video

Treating the Infected Periodontal Foundation
Learn more about the latest understanding of periodontitis and the bacteria that cause it. Watch a video from the late Sigmund Socransky, D.M.D., a dental researcher at the Forsyth Institute, as well as former Associate Clinical Professor of Periodontology at the Harvard University School of Dental Medicine.

REFERENCE: 1. Data on file. OraPharma, Inc. Horsham, PA; 2011. 

84% of patients surveyed want to be educated by you.1

Learn more

Find out how adding ARESTIN® to SRP significantly reduces pocket depth compared to SRP alone. 

INDICATION
ARESTIN® (minocycline HCl) Microspheres, 1 mg is indicated as an adjunct to scaling and root planing (SRP) procedures for reduction of pocket depth in patients with adult periodontitis. ARESTIN® may be used as part of a periodontal maintenance program, which includes good oral hygiene and SRP.

IMPORTANT SAFETY INFORMATION
ARESTIN® should not be used in any patient who has a known sensitivity to minocycline or tetracyclines. The use of drugs of the tetracycline class during tooth development may cause permanent discoloration of the teeth, and therefore should not be used in children or in pregnant or nursing women. Hypersensitivity reactions that included, but were not limited to, anaphylaxis, angioneurotic edema, urticaria, rash, swelling of the face and pruritus have been reported with the use of ARESTIN®. In clinical trials, the most frequently reported nondental treatment-emergent adverse events were headache, infection, flu syndrome and pain.

Please read the Full Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

MyArestinTM is a trademark and ARESTIN® is a registered trademark of OraPharma, Inc.

This site is published by OraPharma, Inc., which is solely responsible for its contents. It is intended for visitors from the United States.

Manufactured for OraPharma, Inc. ©OraPharma, Inc. 2013   A-1373-12   01/13